Zacks.com, a leader in investment research, has aptly noted the recent uptrend in the share price of Keryx Biopharmaceuticals (NASDAQ: KERX, Stock Twits: $KERX) over the last several weeks. Zack’s “SmarTrend” analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time.

A press release from Vicor Technologies, Inc. was released yesterday that basically commented on the state of the industry as it relates to the costs versus the benefits of more thorough testing of athletes to determine the risk of a sudden cardiac incident. It is indeed and eye-opener as to how money rules our world today. The original news link to the PR is provided (linked to Yahoo Finance).

The "Buy on Rumor, Sell on News" mentality certainly has its place in the investment world. Biotechnology stocks are some of the most volatile stocks around and very akin to this way of trading as investors look to get a head start on price movement prior to FDA decisions.